Myelodysplastic syndromes: open trials in Belgium

12 open trials have a site in Belgium. Registry data; only the trial team decides who can take part.

2026-525234-39-00
A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Trial Treatment · Phase 1 · Janssen Cilag International
Universitair Ziekenhuis Antwerpen, Edegem · Universitair Ziekenhuis Gent, Gent · UZ Leuven, Leuven
Registry updated 2026-11-06
NCT07422480
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
Trial Treatment · Phase 3 · Takeda
UZ Leuven, Leuven · Algemeen Ziekenhuis Delta, Roeselare · Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur, Yvoir
Registry updated 2026-11-06
NCT06788509
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Trial Treatment · Phase 1 · Janssen Research & Development, LLC
Universitair Ziekenhuis Gent, Gent
Registry updated 2026-11-04
NCT04628026
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
Trial Treatment · Phase 3 · University of Ulm
Ziekenhuis Aan De Stroom, Antwerp · Az St-Jan Brugge-Oostende A.V., Brugge · Universitair Ziekenhuis Brussel, Brussel · Katholieke Universiteit te Leuven, Leuven · Algemeen Ziekenhuis Delta, Roeselare · CHU UCL NAMUR - Mont Godinne, Yvoir
Registry updated 2026-11-03
NCT07753148
Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation
Trial Treatment · Phase 1 · Regeneron Pharmaceuticals
Ziekenhuis Aan De Stroom, Antwerp · Universitair Ziekenhuis Gent, Gent · UZ Leuven, Leuven · Algemeen Ziekenhuis Delta, Roeselare
Registry updated 2026-10-27
NCT06641414
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Trial Treatment · Phase 3 · Ascentage Pharma Group Inc.
Ziekenhuis Aan De Stroom, Antwerp · Algemeen Ziekenhuis klina, Brasschaat · Az St-Jan Brugge-Oostende A.V., Brugge · Universitair Ziekenhuis Gent, Gent · UZ Leuven, Leuven · Algemeen Ziekenhuis Delta, Roeselare
Registry updated 2026-10-13
NCT04996875
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Trial Treatment · Phase 2 · Cogent Biosciences, Inc.
CHU de Liège, Liège
Registry updated 2026-09-15
2023-504555-27-00
Study comparing thymoglobulin to grafalon, two treatments used to prevent graft versus host disease in elderly patients with acute myeloid leukemia or myelodysplastic syndrome and receiving an allogeneic stem cell transplantation with an unrelated matched donor after a reduced intensity conditioning regimen
Trial Treatment · Phase 3 · Assistance Publique Hopitaux De Paris
Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe
Registry updated 2026-07-15
NCT04064060
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Trial Treatment · Phase 3 · Celgene
Brasschaat · Bruges · Ghent · Leuven
Registry updated 2026-07-01
NCT04988555
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Trial Treatment · Phase 1/2 · Sumitomo Pharma America, Inc.
ZNA Cadix, Antwerp · UZ Ghent, Ghent · University Hospitals Leuven, Leuven · AZ Delta, Roeselare
Registry updated 2026-03-24
NCT03852407
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
Trial Treatment · Phase 2 · University of Liege
Institut Jules Bordet, Anderlecht · Ziekenhuis Aan De Stroom, Antwerp · Az St-Jan Brugge-Oostende A.V., Brugge · Universiteit Gent, Gent · Vrije Universiteit Brussel, Jette · UZ Leuven, Leuven · Algemeen Ziekenhuis Delta, Roeselare · Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe · Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur, Yvoir
Registry updated 2022-10-12
NCT04167696
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
Trial Treatment · Phase 1 · Celyad Oncology SA
UZ Leuven, Leuven · CHU Liège, Liège · AZ Delta, Roeselare
Registry updated 2020-06-09

All Myelodysplastic syndromes trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error